Results 41 to 50 of about 539 (92)

Stimuli‐responsive systems: A focus on controlled drug delivery for posterior segment ocular disease

Responsive Materials, Volume 3, Issue 4, November 2025.
This review highlights recent advances in stimuli‐responsive drug delivery for posterior segment diseases, focusing on mechanisms and potential. It also explores mechanically interlocked molecules and bioorthogonal reactions as novel approaches. Challenges and future perspectives are discussed, aiming to bridge the gap between research and clinical ...
Chengzhi Zhang, Jiayi Hou, Yameng Zhao, Yiwen Wang, Kexin Wang, Siyu Li, Yange Wang, Jiehao Zhang, Shenao Ding, Chenxu Zhang, Zongming Song, Ye Tao   +11 more
wiley   +1 more source

Drug Delivery Technologies for the Treatment of Age‐Related Macular Degeneration

Advanced Science, Volume 12, Issue 39, October 20, 2025.
There are multiple therapeutic agents available for the treatment of both dry age‐related macular degeneration (AMD) and wet AMD. It is essential to continue innovation by introducing new drug delivery technologies that can incorporate those along with patient compliance and the accessibility of the technology into the early stages of research and ...
J Jesus Rodriguez‐Cruz, Jessica Cutrufello, Michael Lam, Shreya Nallaparaju, Nicholas A. Peppas   +4 more
wiley   +1 more source

PTf‐SRiApt Targeting SCAF4‐POLR2A Interaction Suppresses Tumor Growth and Promotes Antitumor Immunity in Triple‐Negative Breast Cancer

Advanced Science, Volume 12, Issue 35, September 18, 2025.
A phosphorothioate‐modified aptamer PTf‐SRiApt capable of disrupting “undruggable” transcription factor SCAF4‐POLR2A interaction with high inhibitory activity and biological stability is presented here. Through this inhibition, PTf‐SRiApt successfully arrested cell cycle progression, induced cell death, and elevated immune recruitment in SCAF4‐POLR2A ...
Liyan Fei, Yichun Pan, Jie Zhai, Tongqing Li, Yuxin Zhou, Sheyu Zhang, Juan Wei, Qian Hu, Xueying Liu, Lu Guo, Weizhu Wu, Yong Wei, Qin Wu, Weihong Tan   +13 more
wiley   +1 more source

Recent Advancements in the Treatment of Age‐Related Macular Degeneration

Med Research, Volume 1, Issue 2, Page 151-169, September 2025.
ABSTRACT Age‐related macular degeneration (AMD) is a prevalent cause of visual impairment and blindness among the elderly. AMD can be categorized into two subtypes: “wet” and “dry.” Current treatments for wet AMD mainly involve anti‐vascular endothelial growth factor (VEGF) drugs, and there are three U.S.
Shan Liu, Danyang Lv, Junran Sun, Huixun Jia, Fang Zheng, Felipe Pereira, Siddharth Narendran, Zhenyu Dong, Haiyun Liu, Shunxiang Gao, Peirong Huang   +10 more
wiley   +1 more source

Correction: Avacincaptad pegol for geographic atrophy secondary to age-related macular degeneration: 18-month findings from the GATHER1 trial. [PDF]

Eye (Lond), 2023
Patel SS, Lally DR, Hsu J, Wykoff CC, Eichenbaum D, Heier JS, Jaffe GJ, Westby K, Desai D, Zhu L, Khanani AM.   +10 more
europepmc   +1 more source

"Izervay (avacincaptad pegol): paving the way for vision preservation in geographic atrophy". [PDF]

Ann Med Surg (Lond)
Shakeel L, Khan A, Akilimali A.
europepmc   +1 more source

Complement inhibitors for the treatment of geographic atrophy. [PDF]

Lancet, 2023
Chew EY.
europepmc   +1 more source

Incomplete Retinal Pigment Epithelium and Outer Retinal Atrophy Characterized Using Fundus Autofluorescence: An 18-Month Post Hoc Analysis of GATHER2. [PDF]

Invest Ophthalmol Vis Sci
Corradetti G, Verma A, Lindenberg S, Nittala MG, Velaga S, Karamat A, He Y, Oncel D, Marion K, Abulon D, Sadda S.   +10 more
europepmc   +1 more source

Understanding the Geographic Atrophy Journey: Patient and Physician Perspectives to Inform Better Care. [PDF]

Ophthalmol Ther
Baker L, Rahhal FM, Gilbert CJ, Leng T.
europepmc   +1 more source

Aptamers in Ocular Disease Therapy and Drug Delivery: Current Progress and Future Opportunities. [PDF]

Curr Ther Res Clin Exp
Durán-Cristiano SC, Ospina-Villa JD, Gijs M.   +2 more
europepmc   +1 more source